Cure8 research brief
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events across the included trials, but the low number of events means uncertainty remains.
Patients with IBD or Crohn's disease discussing JAK inhibitor treatment, gastroenterologists and rheumatologists prescribing upadacitinib, and researchers studying JAK inhibitor safety.
The authors reviewed eight randomized controlled trials including 4,433 patients (about 2,868 treated with upadacitinib). MACE and VTE events were rare in both upadacitinib and comparator groups.
Pooled risk ratios did not show a statistically significant increased risk for MACE or VTE, but confidence intervals were wide because events were uncommon, so the analysis cannot rule out an increased or decreased risk.
Because the pooled trials were limited in event numbers and follow-up, the paper concludes that larger trials and longer-term real-world studies are needed to better define cardiovascular and thromboembolic safety for upadacitinib in these patient groups.
This record is an abstract-level summary of a systematic review and meta-analysis. The pooled trials had few MACE and VTE events and relatively short follow-up for detecting rare cardiovascular outcomes; therefore the results are inconclusive and call for larger or longer-term studies and real-world safety monitoring.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.
